Literature DB >> 20932075

RHCE*ceAR encodes a partial c (RH4) antigen.

C Halter Hipsky1, C Lomas-Francis, A Fuchisawa, M E Reid.   

Abstract

Thr Rh blood group system is highly complex both in the number of discreet antigens and in the existence of partial antigens, especially D and e. Recently, several partial c antigens have been reported. Here we report findings on an African American man with sickle cell disease whose RBCs typed C+c+ and whose plasma contained anti-c. Hemagglutination tests, DNA extraction, PCR-RFLP, reticulocyte RNA isolation, RT-PCR cDNA analyses, cloning, and sequencing were performed by standard procedures. RBCs from the patient typed C+c+ but his plasma contained alloanti-c. DNA analyses showed the presence of RHCE*Ce in trans to RHCE*ceAR with RHD*D and RHD*Weak D type 4.2.2. The amino acid changes on RhceAR are such that C+c+ patient made alloanti-c. This case shows that RhceAR carries a partial c antigen and illustrates the value of DNA testing as an adjunct to hemagglutination to aid in antibody identification in unusual cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20932075

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  3 in total

1.  Insights into RHCE Molecular Analysis in Samples with Partial D Variants: the Experience of Western France.

Authors:  Yann Fichou; Cédric Le Maréchal; Virginie Scotet; Déborah Jamet; Claude Férec
Journal:  Transfus Med Hemother       Date:  2015-07-23       Impact factor: 3.747

Review 2.  Genotyping in Sickle Cell Disease Patients: The French Strategy.

Authors:  Aline Floch; Christophe Tournamille; Btissam Chami; France Pirenne
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

3.  Systematic RH genotyping and variant identification in French donors of African origin.

Authors:  Sandrine Kappler-Gratias; Carine Auxerre; Isabelle Dubeaux; Marylise Beolet; Maryline Ripaux; Pierre-Yves Le Pennec; Bach-Nga Pham
Journal:  Blood Transfus       Date:  2013-06-17       Impact factor: 3.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.